These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33434286)

  • 1. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
    Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
    J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
    Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
    J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
    Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
    Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
    Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
    J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
    Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
    Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Br J Clin Pharmacol; 2022 Jan; 88(1):237-247. PubMed ID: 34169560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.
    Chen J; Gu J; Shah B; Stringer R; Reis da Silva Torrao L; Hackling M; Nidamarthy PK; Prince WT; Woessner R
    J Clin Pharmacol; 2022 Apr; 62(4):520-531. PubMed ID: 34738233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function.
    Sane R; Malhi V; Sutaria DS; Cho E; Twomey P; Craggs C; Wang J; Harris A; Musib L
    J Clin Pharmacol; 2022 Feb; 62(2):171-181. PubMed ID: 34402068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
    Trueman S; Mohamed MF; Feng T; Lacerda AP; Marbury T; Othman AA
    J Clin Pharmacol; 2019 Sep; 59(9):1188-1194. PubMed ID: 30973649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
    Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
    Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
    Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.